Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.81 |
| ▸ | BCR | P11274 | 19/20 | 0.81 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400296 | 1.00 | ABL1 (0.81) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL3400471 | 0.89 | ABL1 (1.00) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL3399079 | 0.85 | ABL1 (0.86) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL13820445 | 0.84 | ABL1 (0.69) | ABL1BCR | |
| SCHEMBL29533631 | 0.84 | ABL1 (0.69) | ABL1BCR | |
| SCHEMBL13820438 | 0.84 | ABL1 (0.73) | ABL1BCR | |
| SCHEMBL16363340 | 0.84 | ABL1 (0.59) | ABL1BCR | |
| SCHEMBL3395214 | 0.84 | ABL1 (1.00) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL16609163 | 0.80 | ABL1 (0.55) | ABL1BCRTTBK1TTBK2 | |
| SCHEMBL3399921 | 0.80 | ABL1 (0.60) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885TTBK1 1939/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885TTBK1 1939/4885 |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885TTBK1 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.